EGFR-dependent pathways of EGFR-TKIs, including gefitinib, erlotinib, and osimertinib, have been well studied, and common mechanisms between them that exert antitumor effects in EGFR mutation-positive lung adenocarcinoma have been demonstrated [15,16,17]. Here, EGFR is linked to lung adenocarcinoma.